CJC-1295 NO DAC 10MG

CJC-1295 is one of the most sought-after peptides for promoting muscle growth, fat loss, recovery, and anti-aging. As a growth hormone-releasing hormone (GHRH) analog, CJC-1295 stimulates your body’s own production of growth hormone (offering many of the benefits associated with HGH therapy without the same risks of exogenous hormone use).

CJC-1295 No DAC is the unmodified version of the CJC-1295 peptide (meaning it does not include the Drug Affinity Complex (DAC) that prolongs half-life).

Without the DAC attachment, CJC-1295 No DAC acts as a short-acting GHRH analog, producing a pulsatile release of growth hormone that more closely mimics the body’s natural GH secretion patterns.

However, because it is metabolized more rapidly, CJC-1295 No DAC has a much shorter half-life (approximately 30 minutes to 2 hours) and is typically administered once or twice per day to achieve consistent effects.

Benefits of CJC-1295 No DAC :

CJC-1295 No DAC offers a different set of advantages (especially for users who want to mimic the body’s natural GH pulse and prioritize recovery, skin health, and anti-aging outcomes).

• Physiologic GH Pulse : Maintain GH receptor sensitivity, support normal feedback loops, promote healthier long-term hormone balance.
• Anti-Aging and Skin Rejuvenation : Enhances collagen synthesis, supports fat metabolism, improves sleep quality.
• Recovery and Joint Support.
• Though less commonly discussed, CJC-1295 No DAC can also be used in injury recovery stacks alongside BPC-157 and TB500.

More Control Over Dosing :

Since CJC-1295 No DAC is short-acting, users can time their injections around training or before bed to maximize specific outcomes:

• Pre-bed dosing to enhance GH pulses during slow-wave sleep
• Post-workout dosing to support muscle recovery and tissue repair
• Reconstitute: Add 3.0 mL bacteriostatic water (6 units = 200mcg)
• Typical daily range: 100-300 mcg once daily (gradual titration).

Dosing Protocol :
Suggested daily titration approach.

• Start: 100-150mcg daily, increase by ~50 mcg every 1-2 weeks as tolerated.
• Target: 200-300 mcg daily by Weeks 5–12.
• Frequency: Once per day (subcutaneous), preferably at bedtime.
• Cycle Length: 8-12 weeks; optional extension to 16 weeks.
• Timing: Administer at bedtime to align with natural nocturnal GH pulses; rotate injection sites.

Weeks 1-2 : 100mcg (=6 units)
Weeks 3-4 : 150mcg (=9 units)
Weeks 5-6 : 200mcg (=12 units)
Weeks 7-12 : 250-300 mcg (=15–18 units)